Watch REVB. Know when insiders buy.
One email the day a filing lands. Free.
REVB
REVELATION BIOSCIENCES, INC.
0.87
+0.00 +0.00%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10.8MNET CASH —52W 0.87 – 6.12SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.7M | −$3.3M | — | -0.87 | −$2.6M | $40K | −$2.6M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$3.1M | −$3M | — | -2.71 | −$3.2M | $72K | −$3.3M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.6M | −$2.5M | — | -14.19 | −$2M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$1.9M | −$1.9M | — | -1.77 | −$1.6M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$2.5M | −$2.4M | — | -28.04 | −$1.9M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$2.1M | −$2.1M | — | -25.34 | −$2.8M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.8M | −$1.7M | — | -698.11 | −$3.7M | −$18K | −$3.7M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$1.8M | −$2.2M | — | -40.15 | −$9.3M | $18K | −$9.3M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$2.5M | −$8.4M | — | -246.27 | −$2.5M | $0 | −$2.5M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$1.9M | −$2.7M | — | -39.37 | −$2.8M | $19K | −$2.9M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.3M | −$2.2M | — | -17.82 | −$2M | — | — | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$2.8M | −$2.6M | — | -9.94 | −$1.7M | $0 | −$1.7M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$9.1M | −$8.9M | — | -23.95 | −$8.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$8M | −$15M | — | -1052.16 | −$18.3M | $19K | −$18.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$8.7M | −$120K | — | -8.44 | −$7.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$10.9M | −$10.8M | — | -149.20 | −$11.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$12M | −$12M | — | -42.50 | −$11.1M | $132K | −$11.2M | $35.5M | — |
| FY2020 · to Dec 31 | — | — | — | −$1.6M | — | -0.68 | −$217K | — | — | — | — |
Every number comes from REVELATION BIOSCIENCES, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.